The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission authorised the use of an esketamine nasal spready under the manufacturer title Spravato to deal with melancholy. However, as of 2021, ketamine has not been accepted by the FDA to treat depression or other psychological wellness https://hallaja952jkl1.jasperwiki.com/user